Enquête spéciale sur l'utilisation de médicaments BENLYSTA®
24 avril 2026 mis à jour par: GlaxoSmithKline
BENLYSTA pour injection intraveineuse/injection sous-cutanée Enquête spéciale sur l'utilisation de drogues
L'objectif de cette étude est de collecter et d'évaluer les informations sur l'innocuité et l'efficacité à long terme de Benlysta pour injection intraveineuse et de Benlysta pour injection sous-cutanée (ci-après dénommé « Benlysta ») dans la pratique clinique quotidienne.
Le but de mener cette enquête sur l'usage de drogues (DUI) chez tous les sujets jusqu'à ce que les données soient accumulées à partir d'un certain nombre de sujets après la commercialisation de Benlysta, des données seront collectées sur la sécurité et l'efficacité de Benlysta à un stade précoce et ainsi de prendre les mesures nécessaires pour une utilisation correcte de Benlysta.
Environ 600 sujets seront inscrits à cette étude.
La période d'observation par sujet sera de 52 semaines à compter du début de l'administration de Benlysta.
BENLYSTA est la marque déposée du groupe de sociétés GlaxoSmithKline (GSK).
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Observationnel
Inscription (Réel)
1514
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Hiroshima, Japon, 730-0001
- GSK Investigational Site
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
Méthode d'échantillonnage
Échantillon de probabilité
Population étudiée
L'étude inclura tous les sujets auxquels Benlysta est administré.
De plus, parmi les sujets qui commencent l'administration après le lancement, ceux à qui Benlysta a déjà administré avant la conclusion du contrat et ceux qui ont déjà commencé l'administration au moment du diagnostic, en raison d'un transfert hospitalier, etc. seront également inclus.
La description
Critère d'intégration:
- L'étude inclura tous les sujets auxquels Benlysta est administré. De plus, parmi les sujets qui commencent l'administration après le lancement, ceux à qui Benlysta a déjà administré avant la conclusion du contrat et ceux qui ont déjà commencé l'administration au moment du diagnostic, en raison d'un transfert hospitalier, etc. seront également inclus.
Critère d'exclusion:
- N / A
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cas uniquement
- Perspectives temporelles: Éventuel
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Benlysta intravenous (IV)
Participants with systemic lupus erythematosus (SLE) received Benlysta via intravenous (IV) administration for 52 weeks as a part of their treatment regimen.
|
Benlysta was administered
|
|
Benlysta subcutaneous (SC)
Participants with SLE received Benlysta via subcutaneous (SC) administration for 52 weeks as a part of their treatment regimen.
|
Benlysta was administered
|
|
Benlysta switched from IV to SC or SC to IV
Participants with SLE received Benlysta for 52 weeks as a part of their treatment regimen, where initial administration was IV but switched to SC, or where the initial administration was SC but switched to IV during the study.
|
Benlysta was administered
|
|
Benlysta IV or SC (Initial route of administration unknown)
Participants with SLE received Benlysta via IV or SC administration for 52 weeks as a part of their treatment regimen.
It was unknown whether the initial administration was IV or SC for participants in this arm.
|
Benlysta was administered
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants With Adverse Drug Reactions (ADRs)
Délai: From the start of the study intervention (Day 1) up to maximum of 3 years
|
ADR is defined as a response to a drug which is noxious and unintended, and which occurred at doses normally used in human for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function.
|
From the start of the study intervention (Day 1) up to maximum of 3 years
|
|
Number of Participants With Serious ADR of Events Defined as a Priority Study Matter
Délai: From the start of the study intervention (Day 1) up to maximum of 3 years
|
ADR is defined as a response to a drug which is noxious and unintended, and which occurred at doses normally used in human for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function.
Following serious ADRs were considered as priority study matter: 1. Serious hypersensitivity, 2. Serious infections (including tuberculosis, pneumonia, pneumocystis pneumonia, sepsis, and opportunistic infection), 3. Reactivation of hepatitis B virus, 4. Progressive multifocal leukoencephalopathy, 5. Interstitial pneumonitis, 6. Malignant tumor, 7. Depression and events related to suicide/self-injury.
|
From the start of the study intervention (Day 1) up to maximum of 3 years
|
|
Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) Score at Week 24
Délai: Baseline (Day 0) and Week 24
|
The SELENA-SLEDAI score is a cumulative and weighted index for assessing systemic lupus erythematosus (SLE) disease activity in participants with SLE.
It consists of 24 disease descriptors related to signs and symptoms, laboratory tests, and physician's assessment across 9 organ systems.
Each descriptor is assigned a weighted score (8 descriptors with a weight of 8 each, 6 descriptors with a weight of 4 each, 7 descriptors with a weight of 2 each, and 3 descriptors with a weight of 1 each) which is added up if the descriptor is observed during a visit or within the preceding 10 days.
The total score ranges from 0 (no disease activity) to 105 (all 24 descriptors present simultaneously).
A higher score indicates a more significant degree of disease activity.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in SELENA SLEDAI Score at Week 52
Délai: Baseline (Day 0) and Week 52
|
The SELENA-SLEDAI score is a cumulative and weighted index for assessing systemic lupus erythematosus (SLE) disease activity in participants with SLE.
It consists of 24 disease descriptors related to signs and symptoms, laboratory tests, and physician's assessment across 9 organ systems.
Each descriptor is assigned a weighted score (8 descriptors with a weight of 8 each, 6 descriptors with a weight of 4 each, 7 descriptors with a weight of 2 each, and 3 descriptors with a weight of 1 each) which is added up if the descriptor is observed during a visit or within the preceding 10 days.
The total score ranges from 0 (no disease activity) to 105 (all 24 descriptors present simultaneously).
A higher score indicates a more significant degree of disease activity.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
|
Change From Baseline in Lupus Impact Tracker Score at Week 24
Délai: Baseline (Day 0) and Week 24
|
Lupus impact tracker is 10-item patient reported outcome tool to measure impact of systemic lupus erythematosus or its treatment on participants' daily lives.
Each answer for items is marked from 0 (none of the time) to 4 (all of the time) points.
Lower the lupus impact score, less impact lupus is having on life of participant.
Total score was derived by adding up scores of all 10 items.
Total score ranges from 0 (less impact on daily life) to 40 (greater impact on daily life).
Higher score indicates greater impact of lupus on quality of life.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in Lupus Impact Tracker Score at Week 52
Délai: Baseline (Day 0) and Week 52
|
Lupus impact tracker is 10-item patient reported outcome tool to measure impact of systemic lupus erythematosus or its treatment on participants' daily lives.
Each answer for items is marked from 0 (none of the time) to 4 (all of the time) points.
Lower the lupus impact score, less impact lupus is having on life of participant.
Total score was derived by adding up scores of all 10 items.
Total score ranges from 0 (less impact on daily life) to 40 (greater impact on daily life).
Higher score indicates greater impact of lupus on quality of life.
|
Baseline (Day 0) and Week 52
|
|
Change From Baseline in Physician's Global Assessment (PGA) Score at Week 24
Délai: Baseline (Day 0) and Week 24
|
The PGA is used to assess the participant's current disease activity by investigator.
It was collected on a 10 centimeter (cm) visual analogue scale (VAS).
The score ranges from 0 (no activity) to 3 (severe activity).
Lower score means no disease activity, higher score means severe disease activity.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in PGA Score at Week 52
Délai: Baseline (Day 0) and Week 52
|
The PGA is used to assess the participant's current disease activity by investigator.
It was collected on a 10 centimeter (cm) visual analogue scale (VAS).
The score ranges from 0 (no activity) to 3 (severe activity).
Lower score means no disease activity, higher score means severe disease activity.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 4
Délai: Baseline (Day 0) and Week 4
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 4
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 8
Délai: Baseline (Day 0) and Week 8
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 8
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 12
Délai: Baseline (Day 0) and Week 12
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 12
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 16
Délai: Baseline (Day 0) and Week 16
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 16
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 20
Délai: Baseline (Day 0) and Week 20
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 20
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 24
Délai: Baseline (Day 0) and Week 24
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 24
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 28
Délai: Baseline (Day 0) and Week 28
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 28
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 32
Délai: Baseline (Day 0) and Week 32
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 32
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 36
Délai: Baseline (Day 0) and Week 36
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 36
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 40
Délai: Baseline (Day 0) and Week 40
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 40
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 44
Délai: Baseline (Day 0) and Week 44
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 44
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 48
Délai: Baseline (Day 0) and Week 48
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 48
|
|
Percent Change From Baseline in Mean Daily Steroid Dose at Week 52
Délai: Baseline (Day 0) and Week 52
|
Mean daily steroid dose was calculated based on the prednisolone equivalent dose.
The average dose over the 7 days prior to and including the assessment date was used as mean daily steroid dose.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
Percent change from Baseline was calculated by dividing change from Baseline value by Baseline value and multiplying it by 100.
|
Baseline (Day 0) and Week 52
|
|
Number of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) Response Criteria at Week 24
Délai: At Week 24
|
LLDAS was defined as a state which, if sustained, was associated with a low likelihood of adverse outcome, considering disease activity and medication safety.
The LLDAS response criteria were: (1) Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) less than equal to (<=)4 and no major active organ involvement (renal, central nervous system, cardiopulmonary, vasculitis, and pyrexia) and without hemolytic anemia or active gastrointestinal lesions; (2) no new signs or symptoms as compared to the last SELENA-SLEDAI assessment; (3) PGA score <=1 (33 millimeter); (4) corticosteroid dose <=7.5 milligram (mg)/day at time of assessment; and (5) use of the same immunosuppressant as compared with prior medication.
No unapproved immunosuppressant drugs like rituximab, anifrolumab, ustekinumab, or baricitinib were used as concomitant medications.
|
At Week 24
|
|
Number of Participants Who Achieved LLDAS Response Criteria at Week 52
Délai: At Week 52
|
LLDAS was defined as a state which, if sustained, was associated with a low likelihood of adverse outcome, considering disease activity and medication safety.
The LLDAS response criteria were: (1) Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) less than equal to (<=)4 and no major active organ involvement (renal, central nervous system, cardiopulmonary, vasculitis, and pyrexia) and without hemolytic anemia or active gastrointestinal lesions; (2) no new signs or symptoms as compared to the last SELENA-SLEDAI assessment; (3) PGA score <=1 (33 millimeter); (4) corticosteroid dose <=7.5 milligram (mg)/day at time of assessment; and (5) use of the same immunosuppressant as compared with prior medication.
No unapproved immunosuppressant drugs like rituximab, anifrolumab, ustekinumab, or baricitinib were used as concomitant medications.
|
At Week 52
|
|
Change From Baseline in Blood Levels of Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Antibody at Week 24
Délai: Baseline (Day 0) and Week 24
|
Blood samples were collected for anti-dsDNA antibody biomarker analysis.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in Blood Levels of Anti-dsDNA Antibody at Week 52
Délai: Baseline (Day 0) and Week 52
|
Blood samples were collected for anti-dsDNA antibody biomarker analysis.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
|
Change From Baseline in Blood Levels of Complement Component-3 (C3) and Complement Component-4 (C4) at Week 24
Délai: Baseline (Day 0) and Week 24
|
Blood samples were collected from participants to assess C3 and C4 levels.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in Blood Levels of Complement Component-3 (C3) and Complement Component-4 (C4) at Week 52
Délai: Baseline (Day 0) and Week 52
|
Blood samples were collected from participants to assess C3 and C4 levels.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
|
Change From Baseline in Blood Levels of Complement Hemolytic Activity at 50% (CH50) at Week 24
Délai: Baseline (Day 0) and Week 24
|
Blood samples were collected from participants to assess CH50 concentrations.
CH50 is a blood test that measures the overall activity of the complement system, a group of proteins crucial for the immune system's function.
Low CH50 levels can be associated with certain infections.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in Blood Levels of Complement Hemolytic Activity at 50% (CH50) at Week 52
Délai: Baseline (Day 0) and Week 52
|
Blood samples were collected from participants to assess CH50 concentrations.
CH50 is a blood test that measures the overall activity of the complement system, a group of proteins crucial for the immune system's function.
Low CH50 levels can be associated with certain infections.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
|
Change From Baseline in Urine Protein/Creatinine Ratio at Week 24
Délai: Baseline (Day 0) and Week 24
|
Urine samples were collected from participants to assess Urine Protein/Creatinine Ratio.
It is a test that estimates how much protein is being excreted in urine, normalized to creatinine.
It's commonly used to assess kidney function and detect proteinuria.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 24
|
|
Change From Baseline in Urine Protein/Creatinine Ratio at Week 52
Délai: Baseline (Day 0) and Week 52
|
Urine samples were collected from participants to assess Urine Protein/Creatinine Ratio.
It is a test that estimates how much protein is being excreted in urine, normalized to creatinine.
It's commonly used to assess kidney function and detect proteinuria.
Baseline was considered as Day 0 of the study.
Change from Baseline was defined as value at the indicated time point minus Baseline value.
|
Baseline (Day 0) and Week 52
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Directeur d'études: GSK Clinical Trials, GlaxoSmithKline
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
15 janvier 2018
Achèvement primaire (Réel)
31 juillet 2025
Achèvement de l'étude (Réel)
31 juillet 2025
Dates d'inscription aux études
Première soumission
6 décembre 2017
Première soumission répondant aux critères de contrôle qualité
6 décembre 2017
Première publication (Réel)
12 décembre 2017
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
18 mai 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
24 avril 2026
Dernière vérification
1 avril 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 207735
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Le lupus érythémateux disséminé
-
University of Alabama at BirminghamRésiliéLymphome anaplasique à grandes cellules | Lymphome T angio-immunoblastique | Lymphomes T périphériques | Leucémie à cellules T de l'adulte | Lymphome T adulte | Lymphome T périphérique Non précisé | T/Null Cell Systemic Type | Lymphome cutané à cellules T avec maladie nodale/viscéraleÉtats-Unis
Essais cliniques sur Benlysta
-
Leiden University Medical CenterGlaxoSmithKlinePas encore de recrutement
-
University Health Network, TorontoGlaxoSmithKlineRecrutement
-
GlaxoSmithKlineRecrutementMaladies pulmonaires interstitiellesÉtats-Unis, Australie, France, Japon, Espagne, Royaume-Uni, Mexique, Belgique, Grèce, Pays-Bas, Chine, Argentine, Canada, Italie, Brésil, Allemagne, Panama, Corée du Sud
-
University of Alabama at BirminghamGlaxoSmithKlineComplétéBronchopneumopathie chronique obstructive | EmphysèmeÉtats-Unis
-
National University Hospital, SingaporeGlaxoSmithKlineRecrutementLe lupus érythémateux disséminéSingapour
-
GlaxoSmithKlineRecrutementLe lupus érythémateux disséminéÉtats-Unis, Espagne, Grèce, Brésil, Argentine, Japon, Le Portugal, Italie, Mexique, Allemagne, France
-
Washington University School of MedicineGlaxoSmithKline; American Cancer Society, Inc.ComplétéMaladie du greffon contre l'hôte | Maladie du greffon contre l'hôteÉtats-Unis
-
Oklahoma Medical Research FoundationGlaxoSmithKlineInconnueLe lupus érythémateux disséminéÉtats-Unis
-
GlaxoSmithKlineRetiréPurpura, thrombocytopénique, idiopathique